Stock Financial Ratios and Split History

RGLS / Regulus Therapeutics Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)87.33
Enterprise Value ($M)73.81
Book Value ($M)35.22
Book Value / Share0.34
Price / Book2.48
NCAV ($M)39.22
NCAV / Share0.38
Price / NCAV2.17
Income Statement (mra) ($M)
Net Income-71.91
Balance Sheet (mrq) ($M)
Cash & Equivalents13.52
Cash / Share0.00
Quick Ratio4.86
Current Ratio4.86
Share Statistics
Common Shares Outstanding103,959,103
Common Stock Shares Outstanding103,955,147
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-2.04
Return on Assets (ROA)-0.76
Return on Equity (ROE)-1.28
Identifiers and Descriptors
Central Index Key (CIK)1505512
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Related CUSIPS
75915K951 75915K901

Split History

Stock splits are used by Regulus Therapeutics Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Pharmaceutical Preparations (2834)

RGLS : Regulus Therapeutics Stock Analysis and Research Report

Regulus Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting micro RNAs to treat diseases with significant unmet medical need. Regulus was formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Ionis Pharmaceuticals, Inc., or Ionis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting micro RNAs pursuant to a license and collaboration agreement. Its most advanced program, under its strategic alliance with Sanofi, is RG-012, an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations, currently with no approved therapy available.

micro RNAs are naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown that an imbalance, or dysregulation, of micro RNAs is dire...

Click for full article

Related News Stories

Regulus Therapeutics' (RGLS) CEO Jay Hagan on Q4 2017 Results - Earnings Call Transcript

2018-03-08 seekingalpha
Good afternoon ladies and gentlemen, and thank you for standing by. Welcome to Regulus Therapeutics Fourth Quarter 2017 Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. (41-1)

Week In Review: Taiwan Liposome Files For $50 Million Secondary IPO In The U.S.

2018-02-25 seekingalpha
Taiwan Liposome (Pending:TLC) (TW:4152), a company developing extended-release delivery of known drugs, filed for a $50 million IPO on the NASDAQ exchange (see story). The company is already listed in Taiwan, where it has a market capitalization of $198 million. TLC has a portfolio of four candidates in clinical development in Taiwan, China, and the US. Last month, TWC formed a Hong Kong JV with Jixi Pharma that will market TLC's drugs in China. (46-1)

Is It Time To Follow Insiders Into Reata Pharmaceuticals?

2017-12-19 seekingalpha
Results for bardoxolone methyl in treating chronic kidney disease caused by Alport syndrome were highly promising. (46-5)

Regulus Therapeutics' (RGLS) CEO Jay Hagan on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good afternoon. My name is Sonya and I will be your conference operator today. At this time, I would like to welcome everyone to the Regulus Therapeutics third quarter 2017 conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you. (41-5)

PepsiCo (PEP) Q3 Earnings Beat Estimates, Revenues Lag

2017-10-04 zacks
PepsiCo, Inc. (PEP - Free Report) is one of the largest food and beverage business in North America and the second largest in the world. The company boasts a diverse portfolio, both geographically and product wise. Its principal brands/businesses include: Frito-Lay snacks, Pepsi-Cola beverages, Gatorade sports drinks, Tropicana juices and Quaker foods. The company has the competitive advantage of selling both snacks and beverages which are complementary food categories. (59-0)

CUSIP: 75915K101